Although data with PSMA-TRT have thus far been very promising in the treatment of prostate cancer, SG damage leading to xerostomia could potentially limit its clinical adaptation, especially when PSMA-TRT with alpha particles is used. This evidence concerns the gene FOLH1 and Familial prostate cancer.